Clinical Trial Update: EXACOS EG Population

View source ↗

Summary

AstraZeneca's EXACOS EG Population trial in chronic obstructive pulmonary disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• EXACOS

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease | Status: WITHDRAWN